Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

AACR 2022 | Combinatorial PARPi therapies in advanced endometrial cancer

Benoit You, MD, PhD, Centre Hospitalier Lyon-Sud, Saint-Genis-Laval, France, discusses potential PARP inhibition based combinatorial therapies for endometrial cancer (EC) following the recent success of similar strategies in ovarian cancer which shares pathological features with EC such as defective homologous recombination. PARP inhibition is being evaluated as a maintenance therapy following chemotherapy and in combination with immunotherapy or anti-angiogenic medicines. This interview took place at the American Association for Cancer Research Annual Meeting in New Orleans, LA.

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.